As an example of lowering the threshold, additional analyses of existing immune‐mediated drug targets (listed in Table S14C, Supporting Information) validated the effects of CTLA4 expression on lung cancer and of METTL3 expression on prostate cancer (Figure S6, Supporting Information). Here, CTLA4 is linked to prostate carcinoma.